Literature DB >> 8872295

Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors.

D J Reis1.   

Abstract

A group of clinically useful antihypertensive agents, including clonidine, moxonidine, and rilmenidine, are all ligands at alpha(2)-adrenergic and imidazoline (I-) receptors, the latter principally of the I1-subclass. These agents all lower blood pressure by reducing the activity of tonically active sympathoexcitatory reticulospinal neurons of the C1 area of the rostroventrolateral medulla (RVL). They tonically excite preganglionic sympathetic neurons in the spinal cord by release of L-glutamate and mediate most reflexes influencing blood pressure. The RVL contains alpha(2)-adrenergic and I1-receptors, and there is evidence to suggest that both receptors may participate in the hypotensive actions of the drugs. However, because only activation of the alpha(2)-adrenergic receptors appears responsible for somnolence, the imidazoline-receptor agonists moxonidine and rilmenidine, both relatively selective for I-receptors, may have superior clinical utility in antihypertensive therapy, since they are sympatholytic and also suppress the generation of angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872295     DOI: 10.1097/00005344-199627003-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

Review 1.  The role of the nervous system in hypertension.

Authors:  J M Wyss; S H Carlson
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Centrally acting antihypertensive drugs: re-emergence of sympathetic inhibition in the treatment of hypertension.

Authors:  C R Benedict
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

3.  Interaction between clonidine and N-methyl-D-aspartate receptors in the caudal ventrolateral medulla of rats.

Authors:  Wei-Zhong Wang; Wen-Jun Yuan; Yan-Xia Pan; Chao-Shu Tang; Ding-Feng Su
Journal:  Exp Brain Res       Date:  2004-05-04       Impact factor: 1.972

4.  Distribution and cellular localization of imidazoleacetic acid-ribotide, an endogenous ligand at imidazol(in)e and adrenergic receptors, in rat brain.

Authors:  Victor L Friedrich; Giorgio P Martinelli; George D Prell; Gay R Holstein
Journal:  J Chem Neuroanat       Date:  2007-01-08       Impact factor: 3.052

5.  Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.

Authors:  Q M Zhu; J D Lesnick; J R Jasper; S J MacLennan; M P Dillon; R M Eglen; D R Blue
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortex.

Authors:  B Szabo; T Fritz; K Wedzony
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 7.  Anatomical observations of the caudal vestibulo-sympathetic pathway.

Authors:  Gay R Holstein; Giorgio P Martinelli; Victor L Friedrich
Journal:  J Vestib Res       Date:  2011       Impact factor: 2.435

8.  Projection neurons of the vestibulo-sympathetic reflex pathway.

Authors:  Gay R Holstein; Victor L Friedrich; Giorgio P Martinelli
Journal:  J Comp Neurol       Date:  2014-06-15       Impact factor: 3.215

9.  Cardiovascular effects of agmatine within the rostral ventrolateral medulla are similar to those of clonidine in anesthetized rats.

Authors:  Jun Yang; Wei-Zhong Wang; Fu-Ming Shen; Ding-Feng Su
Journal:  Exp Brain Res       Date:  2004-10-05       Impact factor: 1.972

10.  Low dose of moxonidine within the rostral ventrolateral medulla improves the baroreflex sensitivity control of sympathetic activity in hypertensive rat.

Authors:  Jia-ling Wang; Long Wang; Zhao-tang Wu; Wen-jun Yuan; Ding-feng Su; Xin Ni; Jian-jun Yan; Wei-zhong Wang
Journal:  Acta Pharmacol Sin       Date:  2009-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.